MetabolicCare Momentum

LLY
NVO
AMGN
+12
15 assetslow risk1d

Rides the wave of companies winning in weight-loss and metabolic health by picking ones already going up.

byAmaltash Advisors LLC
Risk level
Low
Amaltash classification
Minimum
$1,000
to deploy
Licensing
None
no licensing fee
Advisory fee
up to 1.00%
a year

The idea

Rides the wave of companies winning in weight-loss and metabolic health by picking ones already going up.

This strategy bets on the booming weight-loss and metabolic health revolution — and it goes far beyond just the blockbuster drug makers you've heard about on the news. It builds a diversified basket across the entire ecosystem: companies developing next-generation obesity and diabetes treatments, the diagnostic labs helping doctors identify and monitor patients, the device makers tracking metabolic health, the clinics and care delivery platforms scaling treatment access, and even the insurers reshaping how metabolic disease is covered and reimbursed. The strategy focuses exclusively on companies that have already shown sustained upward price momentum over recent years — it's not trying to pick speculative moonshots, but rather ride names that the market has already started rewarding. The basket rotates and rebalances to keep exposure fresh, leaning into the strongest performers while trimming names that lose their footing. It's long-only and growth-oriented, meaning it profits when these companies rise in value — it does not short or hedge. The personality is opportunistic but not reckless: a built-in drawdown guardrail is designed to protect the portfolio if the sector hits a rough patch, targeting a maximum loss limit so a bad quarter doesn't wipe out a good year. Imagine this scenario: A major insurer announces it will cover GLP-1 treatments broadly. Drug makers surge, but so do the glucose monitors, the telehealth obesity clinics, and the cardiac device companies treating downstream complications. This strategy is already holding across all of those layers — capturing the wave rather than just one drop of it.

Design

How it works

  1. Holds 15 companies across drugs, devices, clinics, and insurers in the obesity/diabetes space

  2. Only buys when prices are already climbing and momentum looks healthy

  3. Automatically trims losers and doubles down on winners to stay fresh

  4. Built-in safety brake limits how much you can lose in a bad quarter

Record

How long this strategy has existed

  1. Jul 19, 2026

    Strategy created

  2. Jul 19, 2026

    Version 5 created

This strategy has no live track record of its own yet. Results from accounts that deploy it are not combined into a single history.

Performance

Backtested results are for signed-in investors

We don’t publish hypothetical performance on public pages. Sign in to see this strategy’s backtest after the advisory fee and next to the S&P 500, with the assumptions and risks behind it. Backtested results are not returns any account earned.

Sign in to see the backtest

What it holds

15 assets

PHARMACEUTICAL PREPARATIONS: 33.4%HOSPITAL & MEDICAL SERVICE PLANS: 20%Unclassified: 13.3%SURGICAL & MEDICAL INSTRUMENTS & APPARATUS: 13.3%Other: 20%15assets

Asset mix by sector

  • PHARMACEUTICAL PREPARATIONS33.4%
  • HOSPITAL & MEDICAL SERVICE PLANS20%
  • Unclassified13.3%
  • SURGICAL & MEDICAL INSTRUMENTS & APPARATUS13.3%
  • Other20%

Target weights for version 5. Actual positions vary as the strategy trades and are not shown here.

The Simulation Lab

Ten bad markets, before your money is in one.

Almost anything looks good in a rising market. That is not a test. So we put the strategies listed here through the same ten bad markets, and this one has been through them. They are stretches of real market history, with names and dates: the 2022 slump, the COVID crash, a year that went nowhere. We picked them before this strategy existed.

Two of them are below. Each one shows our drawing of what that market looked like, and the rules this strategy follows when a market like it turns up. None of this is a score. What actually happened to the strategy is in your dashboard, not on this page.

10bad markets, picked before this strategy existed
8 of 10can run on the real trading days of the time they name
2 of 10we model ourselves, and we mark them as modelled
6 Sep 2026when we last ran this strategy through them

When markets fall

The COVID Crash

A third of the market’s value gone in a month — most of it overnight.

our model of the S&P 500 around Feb–Mar 2020falls about 34% at its worst, then ends about 14% below where it begana shape, not a scale · not this strategy

Index
S&P 500
The real dates
19 Feb – 23 Mar 2020
What the index did
fell 33.9%
How we run it
Real trading days

The fastest fall of that size on record: 23 trading days from an all-time high to the bottom. Much of it happened overnight — big companies opened 8-12% below where they had closed the day before.

The rules this strategy follows here

  1. 1
    What it holds

    15 companies.

  2. 2
    When it sells

    One of them drops 6% to 15% below the price it was bought at.

  3. 3
    What it does

    It sells that one. The rest carry on.

On nine days here, the market opened far below where it closed the day before.

An order set to sell at 6% to 15% down can end up selling far below that. If the market opens below that price, there is no chance to sell at it. That is what this market is here to show, and why we keep it in the set.

When markets go nowhere

The Magnificent Seven Year

A handful of big names carried 2023; most stocks didn’t.

our model of the S&P 500 vs its equal-weighted twin around 2023ends about 8% above where it begana shape, not a scale · not this strategy

Index
S&P 500 vs its equal-weighted twin
The real dates
3 Jan – 29 Dec 2023
What the index did
rose 24.2%
How we run it
Real trading days

The cap-weighted index rose 24% while the equal-weighted version managed under 12%: a handful of very large names carried almost the whole gain and the median stock did little.

The rules this strategy follows here

  1. 1
    What it holds

    15 companies.

  2. 2
    When it sells

    One of them drops 6% to 15% below the price it was bought at.

  3. 3
    What it does

    It sells that one. The rest carry on.

No overnight drops in this market.

A market that ends where it started still charges you for every trade made inside it. This is where the cost of trading adds up fastest. That is why it sits in the set right next to the crash.

When markets rise

The Quiet Year

2017 — the calmest year the market has recorded.

our model of the S&P 500 around 2017ends about 12% above where it begana shape, not a scale · not this strategy

Index
S&P 500
The real dates
3 Jan – 29 Dec 2017
What the index did
rose 19.4%

When markets rise

The 2020 Rebound

The market climbed about 76% in under a year off the COVID low.

our model of the S&P 500 around Mar 2020–Feb 2021rises about 85% at its turn, then ends about 78% above where it begana shape, not a scale · not this strategy

Index
S&P 500
The real dates
23 Mar 2020 – 12 Feb 2021
What the index did
rose 75.9%

Sign in to see how this strategy did in each one.

The results open in your dashboard, where we can explain what they mean for you. They are simulated results, so we never show them here.

Open the stress tests

trade.amaltash.com/marketplace/metabolic-care-momentum?tab=stress

All ten markets

  • The Bull Run of 2016–17When markets rise · modelled Tested
  • The 2020 ReboundWhen markets rise · shown above Tested
  • The 2022 SlumpWhen markets fall Tested
  • The COVID CrashWhen markets fall · shown above Tested
  • The Christmas 2018 ScareWhen markets fall Tested
  • The Year That Went NowhereWhen markets go nowhere · modelled Tested
  • The Wild Swings of Late 2022When markets go nowhere Tested
  • The Quiet YearWhen markets rise · shown above Tested
  • The Magnificent Seven YearWhen markets go nowhere · shown above Tested
  • When Tech Handed Over to OilWhen markets go nowhere Tested

These ten are the whole set. We picked them for the damage they did — the fastest crash on record, a year that went nowhere, a grind that punished every rally — not for how they make anything look.

8 of these 10 can run on the real trading days of the time they name. We model the other 2 — The Bull Run of 2016–17 and The Year That Went Nowhere. A strategy needs a stretch of history to warm up on before a test starts, and our price data does not go back far enough to give these that. So we built stand-ins that behave like those years, rather than replays of them. A modelled market is not a forecast, and it is not what would have happened. The shapes drawn above are our models of those markets — never this strategy — and they have no scale. The dates and index moves next to each one are the real figures for the period it is modelled on. Nothing on this page says how any strategy did in these tests.

Fees & minimums

What it costs

Licensing fee, once
None
Advisory fee, yearly
up to 1.00%
Minimum to deploy
$1,000

What $10,000 costs, at a flat balance

1 year

$100

3 years

$300

5 years

$500

The maximum advisory fee. Your actual fee rises and falls with your balance. Other costs, such as spreads and regulatory fees, may apply.

Documents

Risk Disclosure: Trading in financial instruments involves substantial risk, including the possible loss of your entire investment, and may not be suitable for all investors. Prices can be affected by external factors such as financial, regulatory, or political events. Trading on margin or with leverage increases potential losses. Past performance is not indicative of future results.

Not Financial Advice: The information provided on this platform is for informational purposes only and does not constitute investment, financial, or trading advice. We do not recommend any particular trading strategy or instrument. Please conduct your own research and consult with a qualified financial advisor before making investment decisions.

Get Started

Ready to Deploy This Strategy?

Connect your brokerage account and turn on the strategy. We then place trades that follow its rules and your limits. No coding needed.

Start Trading Now →

No licensing fee

+ up to 1.00%/yr

Sign in to deploy